Core Viewpoint - Alpha Tau Medical Ltd. has appointed Ms. Maya Netser to its Board of Directors, marking a significant leadership change as the company expands its cancer treatment capabilities [1][2]. Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of the Alpha DaRT technology for treating solid tumors [6]. - The Alpha DaRT technology utilizes radium-224 for targeted alpha-irradiation of tumors, aiming to minimize damage to surrounding healthy tissue [8]. Leadership Changes - Ms. Maya Netser brings over 25 years of experience in corporate leadership and advisory roles, including her previous position as CEO of Cabaret Biotech, which was acquired by Kite Pharma and Gilead Sciences [2][3]. - Mr. Meir Jakobsohn has completed his term on the Board but will continue to serve in an advisory capacity, having contributed significantly to the company's growth [4][5]. Strategic Direction - The company is at a strategic inflection point, focusing on expanding its treatment capabilities to internal organs, which is seen as a promising opportunity for growth [2].

JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, announced today that it has been accepted into the prestigious Total Product Life Cycle (TPLC) Advisory Program (“TAP”) Pilot of the U.S. Food and Drug Administration (“FDA”), to accelerate market access to the Alpha DaRT for patients with recurrent glioblastoma multiforme (“GBM”). This acceptance follows the Com ...

JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that its first patient with recurrent lung cancer has been treated, in a clinical trial at Hadassah Medical Center in Jerusalem, Israel. The trial is designed to treat up to ten patients with recurrent tumors in the mediastinum area of the chest, and allows for the use of concurrent chemotherapy, ...

JERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using the Alpha DaRT. The clinical study, whi ...

- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to-treat superficial cancers, with an overall response rate of almost 100% in treated lesions, no moderate or severe longterm toxicities noted, and a 2-year local recurrence-free survival was estimated at 77% - - Cash, cash equivalents & deposits balance of $74.1 million with runway of at least two years - JERUSALEM, Aug. 14, 2024 (GLOBE ...

Exhibit 99.1 ALPHA TAU MEDICAL LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page | --- | --- | |----------------------------------------------------------------------------------|------------| | | | | Interim Consolidated Balance Sheets | 2 – 3 | | | | | Interim Consolidated Statements of Operations | 4 | | Interim Consolidated Statements of Changes in Shareholders' Equity | 5 | | | | | Interim Consolidated Statements of Cash Flows | 6 | | | | ...

The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in treated lesions and a complete response rate of 89%. With follow-up as long as 51 months (median follow-up of 14-months), no moderate or severe long-term toxicities were noted, and 2-year local recurrence-free survival was estimated at 77%. JERUSALEM, June 25, 2024 (GLO ...

decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it. Alpha Tau CEO Uzi Sofer stated, "We are encouraged by the perspective offered by this long-term data and its publication in a renowned journal such as Cancers. The publication of this comprehensive pooled ...

Company Overview - Alpha Tau Medical Ltd. is an Israeli medical device company founded in 2016, focusing on the research, development, and potential commercialization of the Alpha DaRT for treating solid tumors [2] - The technology was developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University [2] Product Information - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed for highly potent and conformal alpha-irradiation of solid tumors through intratumoral delivery of radium-224 impregnated sources [3] - The therapy aims to destroy tumors by releasing high-energy alpha particles from decaying radium, which primarily affects the tumor while sparing surrounding healthy tissue due to the short diffusion distance of alpha-emitting atoms [3] Upcoming Events - The CFO of Alpha Tau, Raphi Levy, will present a corporate overview and update at the Jefferies Global Healthcare Conference on June 5th, 2024, from 1:30 to 1:55 PM EST in New York, NY [1] - Mr. Levy will also be available for one-on-one investor meetings during the conference [1]

Core Insights - Alpha Tau Medical Ltd. reported significant advancements in its clinical trials and financial results for Q1 2024, highlighting the ongoing development of its Alpha DaRT cancer therapy [1][2]. Financial Performance - For the quarter ended March 31, 2024, the company reported R&D expenses of $6.4 million, slightly up from $6.3 million in Q1 2023, attributed to increased employee compensation and benefits [5]. - The net loss for Q1 2024 was $8.0 million, or $0.11 per share, compared to a net loss of $8.2 million, or $0.12 per share, in the same period of 2023 [8][19]. - As of March 31, 2024, the company had cash and cash equivalents totaling $80.7 million, down from $84.9 million at the end of 2023, with an expected runway of at least two years [9]. Clinical Developments - The company presented preclinical data at the ESTRO 2024 Congress, demonstrating an abscopal immune effect in pancreatic murine tumor models, indicating a significant reduction in distant tumor growth rates [5]. - The first patient with liver metastases was treated in a feasibility and safety study of Alpha DaRT at McGill University Health Center, aiming to recruit up to 10 patients [5]. - Ongoing recruitment for the ReSTART U.S. multi-center pivotal trial and pancreatic cancer feasibility studies in Canada and Israel is currently in progress [1][5]. Upcoming Milestones - The company plans to treat the first patient in the Israeli recurrent lung cancer safety and feasibility trial in Q2 2024 and aims to complete patient recruitment for the ReSTART trial in H2 2024 [5]. - Alpha Tau anticipates a response from PMDA in Japan by the end of 2024 regarding pre-market approval for Alpha DaRT in patients with recurrent head and neck cancer [5]. Corporate Strategy - The CEO emphasized the focus on advancing the ReSTART trial while also preparing for potential product launches and solidifying the supply chain, including plans for a new manufacturing facility in Hudson, New Hampshire [2].